China tests new anti-coronavirus drug on patients – Xinhua

This news has been read 16666 times!

BEIJING, Feb 6 (KUNA) — The registration for clinical trials on the antiviral drug ‘Remdesivir’ has been approved as the first batch of patients infected with the 2019 novel coronavirus (2019-nCoV) began to take it on Thursday.
Head of the drug’s clinical trial program Cao Bin said at a press conference that this approval was supported by the Ministry of Science and Technology, the National Health Commission and the National Medical Products Administration, according to Xinhua News Agency.

In this undated frame from video provided by the National Institute of Allergy and Infectious Diseases (NIAID), a scientist returns a novel coronavirus vaccine sample to a freezer in Bethesda, Md. The flu-like virus that exploded from China has researchers worldwide once again scrambling to find a vaccine against a surprise health threat, with no guarantee one will arrive in time. (NIAID via AP)


Remdesivir, developed by the US-based pharmaceutical company Gilead Sciences, showed good activity against Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronavirus in previous experiments on cells and animals, which will be applied to 761 infected patients, he explained.

This news has been read 16666 times!

Related Articles

Back to top button

Advt Blocker Detected

Kindly disable the Ad blocker

Verified by MonsterInsights